Search Results (34)

Arthritis and arthrosis are prevalent joint diseases that cause pain and disability, and their early diagnosis is crucial for preventing irreversible damage. Conventional diagnostic methods such as X-ray, ultrasound, and MRI have limitations in early detection, prompting interest in alternative techniques. This work presents the design and clinical evaluation of a prototype device for non-invasive early diagnosis of arthritis (inflammatory joint disease) and arthrosis (osteoarthritis) using infrared thermography and deep neural networks. The portable prototype integrates a Raspberry Pi 4 microcomputer, an infrared thermal camera, and a touchscreen interface, all housed in a 3D-printed PLA enclosure. A custom Flask-based application enables two operational modes: (1) thermal image acquisition for training data collection, and (2) automated diagnosis using a pre-trained ResNet50 deep learning model. A clinical study was conducted at a university clinic in a temperature-controlled environment with 100 subjects (70% with arthritic conditions and 30% healthy). Thermal images of both hands (four images per hand) were captured for each participant, and all patients provided informed consent. The ResNet50 model was trained to classify three classes (healthy, arthritis, and arthrosis) from these images. Results show that the system can effectively distinguish healthy individuals from those with joint pathologies, achieving an overall test accuracy of approximately 64%. The model identified healthy hands with high confidence (100% sensitivity for the healthy class), but it struggled to differentiate between arthritis and arthrosis, often misclassifying one as the other. The prototype’s multiclass ROC (Receiver Operating Characteristic) analysis further showed excellent discrimination between healthy vs. diseased groups (AUC, Area Under the Curve ~1.00), but lower performance between arthrosis and arthritis classes (AUC ~0.60–0.68). Despite these challenges, the device demonstrates the feasibility of AI-assisted thermographic screening: it is completely non-invasive, radiation-free, and low-cost, providing results in real-time. In the discussion, we compare this thermography-based approach with conventional diagnostic modalities and highlight its advantages, such as early detection of physiological changes, portability, and patient comfort. While not intended to replace established methods, this technology can serve as an early warning and triage tool in clinical settings. In conclusion, the proposed prototype represents an innovative application of infrared thermography and deep learning for joint disease screening. With further improvements in classification accuracy and broader validation, such systems could significantly augment current clinical practice by enabling rapid and non-invasive early diagnosis of arthritis and arthrosis. Full article

Sarcopenia, a progressive age-related loss of skeletal muscle mass, strength, and function, is a major contributor to disability, reduced quality of life, and mortality in older adults. While current diagnostic approaches, such as dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), magnetic resonance imaging (MRI), and computed tomography (CT), are widely used to assess muscle mass, they have limitations in detecting early qualitative changes in muscle architecture and composition. Shear Wave Elastography (SWE), an ultrasound-based technique that quantifies tissue stiffness, has emerged as a promising tool to evaluate both muscle quantity and quality in a non-invasive, portable, and reproducible manner. Studies suggest that SWE can detect alterations in muscle mechanical properties associated with sarcopenia, providing complementary information to traditional morphometric assessments. Preliminary evidence indicates its good reproducibility, feasibility in various clinical settings, and potential for integration into routine evaluations. This narrative review summarizes current evidence on the use of SWE for the assessment of sarcopenia across diverse populations. Full article

The risk of developing symptomatic knee osteoarthritis (KOA) during a lifetime, i.e., pain, aching, or stiffness in a joint associated with radiographic KOA, was estimated in 2008 to be around 40% in men and 47% in women. The clinical and scientific communities lack an efficient diagnostic method to effectively monitor, evaluate, and predict the evolution of KOA before and during the therapeutic protocol. In this review, we summarize the main methods that are used or seem promising for the diagnosis of osteoarthritis, with a specific focus on non- or low-invasive methods. As standard diagnostic tools, arthroscopy, magnetic resonance imaging (MRI), and X-ray radiography provide spatial and direct visualization of the joint. However, discrepancies between findings and patient feelings often occur, indicating a lack of correlation between current imaging methods and clinical symptoms. Alternative strategies are in development, including the analysis of biochemical markers or acoustic emission recordings. These methods have undergone deep development and propose, with non- or minimally invasive procedures, to obtain data on tissue condition. However, they present some drawbacks, such as possible interference or the lack of direct visualization of the tissue. Other original methods show strong potential in the field of KOA monitoring, such as electrical bioimpedance or near-infrared spectrometry. These methods could permit us to obtain cheap, portable, and non-invasive data on joint tissue health, while they still need strong implementation to be validated. Also, the use of Artificial Intelligence (AI) in the diagnosis seems essential to effectively develop and validate predictive models for KOA evolution, provided that a large and robust database is available. This would offer a powerful tool for researchers and clinicians to improve therapeutic strategies while permitting an anticipated adaptation of the clinical protocols, moving toward reliable and personalized medicine. Full article

Background/Objectives: Two-dimensional echocardiography (2D echo) is widely used for assessing left ventricular ejection fraction (LVEF). This single-center comparative study aims to evaluate the accuracy of LVEF measurements obtained using the AI-assisted handheld ultrasound device Kosmos against cardiac magnetic resonance (CMR), the current gold standard. Methods: A total of 49 adult patients undergoing clinically indicated CMR were prospectively enrolled. AI-based LVEF measurements were compared with CMR using the Wilcoxon signed-rank test, Pearson correlation, multivariable linear regression, and Bland–Altman analysis. All analyses were performed using STATA v18.0. Results: Median LVEF was 57% (CMR) vs. 55% (AI-Echo), with no significant difference (p = 0.51). Strong correlation (r = 0.99) and minimal bias (1.1%) were observed. Conclusions: The Kosmos AI-based autoEF algorithm demonstrated excellent agreement with CMR-derived LVEF values. Its speed and automation make it promising for bedside assessment in emergency departments, intensive care units, and outpatient clinics. This study aims to fill the gap in current clinical evidence by evaluating, for the first time, the agreement between LVEF measurements obtained via Kosmos’ AI-assisted autoEF and those from cardiac MRI (CMR), the gold standard for ventricular function assessment. This comparison is critical for validating the reliability of portable AI-driven echocardiographic tools in real-world clinical practice. However, these findings derive from a selected population at a single Italian center and should be validated in larger, diverse cohorts before assuming global generalizability. Full article

Musculoskeletal (MSK) disorders remain a major global cause of disability, with diagnostic complexity arising from their heterogeneous presentation and multifactorial pathophysiology. Recent advances across imaging modalities, molecular biomarkers, artificial intelligence applications, and point-of-care technologies are fundamentally reshaping musculoskeletal diagnostics. This review offers a novel synthesis by unifying recent innovations across multiple diagnostic imaging modalities, such as CT, MRI, and ultrasound, with emerging biochemical, genetic, and digital technologies. While existing reviews typically focus on advances within a single modality or for specific MSK conditions, this paper integrates a broad spectrum of developments to highlight how use of multimodal diagnostic strategies in combination can improve disease detection, stratification, and clinical decision-making in real-world settings. Technological developments in imaging, including photon-counting detector computed tomography, quantitative magnetic resonance imaging, and four-dimensional computed tomography, have enhanced the ability to visualize structural and dynamic musculoskeletal abnormalities with greater precision. Molecular imaging and biochemical markers such as CTX-II (C-terminal cross-linked telopeptides of type II collagen) and PINP (procollagen type I N-propeptide) provide early, objective indicators of tissue degeneration and bone turnover, while genetic and epigenetic profiling can elucidate individual patterns of susceptibility. Point-of-care ultrasound and portable diagnostic devices have expanded real-time imaging and functional assessment capabilities across diverse clinical settings. Artificial intelligence and machine learning algorithms now automate image interpretation, predict clinical outcomes, and enhance clinical decision support, complementing conventional clinical evaluations. Wearable sensors and mobile health technologies extend continuous monitoring beyond traditional healthcare environments, generating real-world data critical for dynamic disease management. However, standardization of diagnostic protocols, rigorous validation of novel methodologies, and thoughtful integration of multimodal data remain essential for translating technological advances into improved patient outcomes. Despite these advances, several key limitations constrain widespread clinical adoption. Imaging modalities lack standardized acquisition protocols and reference values, making cross-site comparison and clinical interpretation difficult. AI-driven diagnostic tools often suffer from limited external validation and transparency (“black-box” models), impacting clinicians’ trust and hindering regulatory approval. Molecular markers like CTX-II and PINP, though promising, show variability due to diurnal fluctuations and comorbid conditions, complicating their use in routine monitoring. Integration of multimodal data, especially across imaging, omics, and wearable devices, remains technically and logistically complex, requiring robust data infrastructure and informatics expertise not yet widely available in MSK clinical practice. Furthermore, reimbursement models have not caught up with many of these innovations, limiting access in resource-constrained healthcare settings. As these fields converge, musculoskeletal diagnostics methods are poised to evolve into a more precise, personalized, and patient-centered discipline, driving meaningful improvements in musculoskeletal health worldwide. Full article

Degenerative joint disease remains a leading cause of global disability, with early diagnosis posing a significant clinical challenge due to its gradual onset and symptom overlap with other musculoskeletal disorders. This review focuses on emerging diagnostic strategies by synthesizing evidence specifically from studies that integrate biochemical biomarkers, advanced imaging techniques, and machine learning models relevant to osteoarthritis. We evaluate the diagnostic utility of cartilage degradation markers (e.g., CTX-II, COMP), inflammatory cytokines (e.g., IL-1β, TNF-α), and synovial fluid microRNA profiles, and how they correlate with quantitative imaging readouts from T2-mapping MRI, ultrasound elastography, and dual-energy CT. Furthermore, we highlight recent developments in radiomics and AI-driven image interpretation to assess joint space narrowing, osteophyte formation, and subchondral bone changes with high fidelity. The integration of these datasets using multimodal learning approaches offers novel diagnostic phenotypes that stratify patients by disease stage and risk of progression. Finally, we explore the implementation of these tools in point-of-care diagnostics, including portable imaging devices and rapid biomarker assays, particularly in aging and underserved populations. By presenting a unified diagnostic pipeline, this article advances the future of early detection and personalized monitoring in joint degeneration. Full article

Breast cancer remains a leading cause of cancer-related deaths among women, emphasizing the critical need for early detection and monitoring techniques. Conventional imaging modalities such as mammography, MRI, and ultrasound have face sensitivity, specificity, cost, and patient comfort limitations. This study introduces a handheld Near-Infrared Diffuse Optical Tomography (NIR DOT) probe for breast cancer imaging. The NIRscan probe utilizes multi-wavelength light-emitting diodes (LEDs) and a linear charge-coupled device (CCD) sensor to acquire real-time optical data, reconstructing cross-sectional images of breast tissue based on scattering and absorption coefficients. With wavelengths optimized for the differential optical properties of tissue components, the probe enables functional imaging, distinguishing between healthy and malignant tissues. Clinical evaluations have demonstrated its potential for precise tumor localization and monitoring therapeutic responses, achieving a sensitivity of 94.7% and specificity of 84.2%. By incorporating machine learning algorithms and a modified diffusion equation (MDE), the system enhances the accuracy and speed of image reconstruction, supporting rapid, non-invasive diagnostics. This development represents a significant step forward in portable, cost-effective solutions for breast cancer detection, with potential applications in low-resource settings and diverse clinical environments. Full article

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder and a significant cause of dementia in elderly individuals, with a growing prevalence in our aging population. Extracellular amyloid-β peptides (Aβ), intracellular tau proteins, and their phosphorylated forms have gained prominence as critical biomarkers for early and precise diagnosis of AD, correlating with disease progression and response to therapy. The high costs and invasiveness of conventional diagnostic methods, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), limit their suitability for large-scale or routine screening. However, electrochemical (EC) analysis methods have made significant progress in disease detection due to their high sensitivity, excellent specificity, portability, and cost-effectiveness. This article reviews the progress in EC biosensing technologies, focusing on the detection of tau protein biomarkers in the blood (a low-invasive, accessible diagnostic medium). The article then discusses various EC sensing platforms, including their fabrication processes, limit of detection (LOD), sensitivity, and clinical potential to show the role of these sensors as transformers changing the face of AD diagnostics. Full article

In clinical settings, computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) are commonly employed in brain imaging to assist clinicians in determining the type of stroke in patients. However, these modalities are associated with potential hazards or limitations. In contrast, microwave imaging emerges as a promising technique, offering advantages such as non-ionizing radiation, low cost, lightweight, and portability. The primary challenges faced by microwave tomography include the severe ill-posedness of the electromagnetic inverse scattering problem and the time-consuming nature and unsatisfactory resolution of iterative quantitative algorithms. This paper proposes a learning electric field enhancement imaging method (LEFEIM) to achieve quantitative brain imaging based on a microwave tomography system. LEFEIM comprises two cascaded networks. The first, based on a convolutional neural network, utilizes the electric field from the receiving antenna to predict the electric field distribution within the imaging domain. The second network employs the electric field distribution as input to learn the dielectric constant distribution, thereby realizing quantitative brain imaging. Compared to the Born Iterative Method (BIM), LEFEIM significantly improves imaging time, while enhancing imaging quality and goodness-of-fit to a certain extent. Simultaneously, LEFEIM exhibits anti-noise capabilities. Full article

The timely detection and accurate localization of brain tumors is crucial in preserving people’s quality of life. Thankfully, intelligent computational systems have proven invaluable in addressing these challenges. In particular, the UNET model can extract essential pixel-level features to automatically identify the tumor’s location. However, known deep learning-based works usually directly feed the 3D volume into the model, which causes excessive computational complexity. This paper presents an approach to boost the UNET network, reducing computational workload while maintaining superior efficiency in locating brain tumors. This concept could benefit portable or embedded recognition systems with limited resources for operating in real time. This enhancement involves an automatic slice selection from the MRI T2 modality volumetric images containing the most relevant tumor information and implementing an adaptive learning rate to avoid local minima. Compared with the original model (7.7 M parameters), the proposed UNET model uses only 2 M parameters and was tested on the BraTS 2017, 2020, and 2021 datasets. Notably, the BraTS2021 dataset provided outstanding binary metric results: 0.7807 for the Intersection Over the Union (IoU), 0.860 for the Dice Similarity Coefficient (DSC), 0.656 for the Sensitivity, and 0.9964 for the Specificity compared to vanilla UNET. Full article

Background/Objectives: Imaging studies are often an integral part of patient evaluation and serve as the primary means of communication between radiologists and referring physicians. This study aimed to evaluate brain Magnetic Resonance Imaging (MRI) reports and to determine whether these reports follow a standardized or narrative format. Methods: A series of 466 anonymized MRI reports from an academic hospital were downloaded from the Picture Archiving and Communication System (PACS) in portable document format (pdf) for the period between August 2017 and March 2018. Two hundred brain MRI reports, written by four radiologists, were compared to a structured report template from the Radiology Society of North America (RSNA) and were included, whereas MR-modified techniques, such as MRI orbits and MR venography reports, were excluded (n = 266). All statistical analyses were conducted using Statistical Package for the Social Sciences (SPSS) statistical software (version 16.4.1, MedCalc Software). Results: None of the included studies used the RSNA template for structured reports (SRs). The highest number of brain-reported pathologies was for vascular disease (24%), while the lowest was for infections (3.5%) and motor dysfunction (5.5%). Radiologists specified the Technique (n = 170, 85%), Clinical Information (n = 187, 93.5%), and Impression (n = 197, 98.5%) in almost all reports. However, information in the Findings section was often missing. As hypothesized, radiologists with less experience showed a greater commitment to reporting additional elements than those with more experience. Conclusions: The SR template for medical imaging has been accessible online for over a decade. However, many hospitals and radiologists still use the free-text style for reporting. Our study was conducted in an academic hospital with a fellowship program, and we found that structured reporting had not yet been implemented. As the health system transitions towards teleservices and teleradiology, more efforts need to be put into advocating standardized reporting in medical imaging. Full article

Early detection of acute brain injury (ABI) is critical to intensive care unit (ICU) patient management and intervention to decrease major complications. Head CT (HCT) is the standard of care for the assessment of ABI in ICU patients; however, it has limited sensitivity compared to MRI. We retrospectively compared the ability of ultra-low-field portable MR (ULF-pMR) and head HCT, acquired within 24 h of each other, to detect ABI in ICU patients supported on extracorporeal membrane oxygenation (ECMO). A total of 17 adult patients (median age 55 years; 47% male) were included in the analysis. Of the 17 patients assessed, ABI was not observed on either ULF-pMR or HCT in eight patients (47%). ABI was observed in the remaining nine patients with a total of 10 events (8 ischemic, 2 hemorrhagic). Of the eight ischemic events, ULF-pMR observed all eight, while HCT only observed four events. Regarding hemorrhagic stroke, ULF-pMR observed only one of them, while HCT observed both. ULF-pMR outperformed HCT for the detection of ABI, especially ischemic injury, and may offer diagnostic advantages for ICU patients. The lack of sensitivity to hemorrhage may improve with modification of the imaging acquisition program. Full article

This paper developed a comprehensive magnetic resonance imaging (MRI)-compatible electrophysiological (EP) acquisition system, which can acquire various physiological electrical signals, including electrocardiography (ECG), electromyography (EMG), electroencephalography (EEG) and electrocorticogram (ECoG), and EP recording combined with multimodal stimulation. The system is designed to be compatible with the 7-Tesla (7T) ultra-high field MRI environment, providing convenience for neuroscience and physiological research. To achieve MRI compatibility, the device uses magnetically compatible materials and shielding measures on the hardware and algorithm processing on the software side. Different filtering algorithms are adopted for different signals to suppress all kinds of interference in the MRI environment. The system can allow input signals up to ±0.225 V and channels up to 256. The equipment has been tested and proven to be able to collect a variety of physiological electrical signals effectively. When scanned under the condition of a 7T high-intensity magnetic field, the system does not generate obvious heating and can meet the safety requirements of MRI and EEG acquisition requirements. Moreover, an algorithm is designed and improved to efficiently and automatically remove the gradient artifact (GA) noise generated by MRI, which is a thousand-fold gradient artifact. Overall, this work proposes a complete, portable, MRI-compatible system that can collect a variety of physiological electrical signals and integrate more efficient GA removal algorithms. Full article

Alzheimer’s disease (AD) is the most common neurological disease and a serious cause of dementia, which constitutes a threat to human health. The clinical evidence has found that extracellular amyloid-beta peptides (Aβ), phosphorylated tau (p-tau), and intracellular tau proteins, which are derived from the amyloid precursor protein (APP), are the leading biomarkers for accurate and early diagnosis of AD due to their central role in disease pathology, their correlation with disease progression, their diagnostic value, and their implications for therapeutic interventions. Their detection and monitoring contribute significantly to understanding AD and advancing clinical care. Available diagnostic techniques, including magnetic resonance imaging (MRI) and positron emission tomography (PET), are mainly used to validate AD diagnosis. However, these methods are expensive, yield results that are difficult to interpret, and have common side effects such as headaches, nausea, and vomiting. Therefore, researchers have focused on developing cost-effective, portable, and point-of-care alternative diagnostic devices to detect specific biomarkers in cerebrospinal fluid (CSF) and other biofluids. In this review, we summarized the recent progress in developing electrochemical immunosensors for detecting AD biomarkers (Aβ and p-tau protein) and their subtypes (AβO, Aβ_(1-40), Aβ_(1-42), t-tau, cleaved-tau (c-tau), p-tau₁₈₁, p-tau₂₃₁, p-tau₃₈₁, and p-tau₄₄₁). We also evaluated the key characteristics and electrochemical performance of developed immunosensing platforms, including signal interfaces, nanomaterials or other signal amplifiers, biofunctionalization methods, and even primary electrochemical sensing performances (i.e., sensitivity, linear detection range, the limit of detection (LOD), and clinical application). Full article

Dementias that develop in older people test the limits of modern medicine. As far as dementia in older people goes, Alzheimer’s disease (AD) is by far the most prevalent form. For over fifty years, medical and exclusion criteria were used to diagnose AD, with an accuracy of only 85 per cent. This did not allow for a correct diagnosis, which could be validated only through postmortem examination. Diagnosis of AD can be sped up, and the course of the disease can be predicted by applying machine learning (ML) techniques to Magnetic Resonance Imaging (MRI) techniques. Dementia in specific seniors could be predicted using data from AD screenings and ML classifiers. Classifier performance for AD subjects can be enhanced by including demographic information from the MRI and the patient’s preexisting conditions. In this article, we have used the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. In addition, we proposed a framework for the AD/non-AD classification of dementia patients using longitudinal brain MRI features and Deep Belief Network (DBN) trained with the Mayfly Optimization Algorithm (MOA). An IoT-enabled portable MR imaging device is used to capture real-time patient MR images and identify anomalies in MRI scans to detect and classify AD. Our experiments validate that the predictive power of all models is greatly enhanced by including early information about comorbidities and medication characteristics. The random forest model outclasses other models in terms of precision. This research is the first to examine how AD forecasting can benefit from using multimodal time-series data. The ability to distinguish between healthy and diseased patients is demonstrated by the DBN-MOA accuracy of 97.456%, f-Score of 93.187 %, recall of 95.789 % and precision of 94.621% achieved by the proposed technique. The experimental results of this research demonstrate the efficacy, superiority, and applicability of the DBN-MOA algorithm developed for the purpose of AD diagnosis. Full article